Scarica l'app Stockscreener
79.76
1.31%
-1.06
Dopo l'orario di chiusura:
79.76
Precedente Chiudi:
$80.82
Aprire:
$80.35
Volume 24 ore:
1.98M
Relative Volume:
0.83
Capitalizzazione di mercato:
$12.92B
Reddito:
$705.14M
Utile/perdita netta:
$-453.90M
Rapporto P/E:
-26.24
EPS:
-3.04
Flusso di cassa netto:
$-551.29M
1 W Prestazione:
-2.15%
1M Prestazione:
+11.47%
6M Prestazione:
+124.11%
1 anno Prestazione:
+117.86%
Intervallo 1D:
$79.31
$81.00
Intervallo di 1 settimana:
$77.79
$81.22
Portata 52W:
$23.95
$83.61
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Confronta IONS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
79.76 | 13.09B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2025-09-03 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Neutral |
| 2024-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Ripresa | Jefferies | Buy |
| 2024-06-14 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Ionis Pharmaceuticals (IONS): Leerink Partners Raises Price Targ - GuruFocus
Squarepoint Ops LLC Sells 170,978 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercial - pharmiweb.com
Ionis to hold third quarter 2023 financial results webcast - GuruFocus
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Hudson Bay Capital Management LP - MarketBeat
Marex Group plc Buys New Shares in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Hudson Bay Capital Management LP Has $29.63 Million Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Levels Update: Can Ionis Pharmaceuticals Inc stock sustain market leadershipJuly 2025 Review & Real-Time Volume Trigger Notifications - moha.gov.vn
Adage Capital Partners GP L.L.C. Raises Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study - MSN
Ionis Pharmaceuticals Sees Rapid Rise On RNA Drug Progress - Finimize
B of A Securities Maintains Ionis Pharmaceuticals (IONS) Buy Recommendation - Nasdaq
Ionis Pharmaceuticals (IONS) Price Target Raised by B of A Securities | IONS Stock News - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $97.00 - MarketBeat
Angioedema Pipeline 2025: FDA Approvals and Clinical Trials - openPR.com
450,254 Shares in Ionis Pharmaceuticals, Inc. $IONS Acquired by Norges Bank - MarketBeat
Polycythemia Vera Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharm - Barchart.com
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com
Can Ionis Pharmaceuticals Stock Hold Up When Markets Turn? - Trefis
Has Ionis Pharmaceuticals Run Too Far After 135% Surge and Bullish DCF Outlook? - Yahoo Finance
Ionis Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
How Twin FDA Breakthrough Therapy Wins Could Impact Ionis Pharmaceuticals (IONS) Investors - Sahm
Kennedy Capital Management LLC Has $5.22 Million Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Hsbc Holdings PLC Purchases 33,461 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Capital Fund Management S.A. Sells 26,795 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) Director Sells $2,262,960.00 in Stock - MarketBeat
Rx Rundown: Bristol Myers Squibb, Retro Bio, Ionis Pharmaceuticals and more - Medical Marketing and Media
Is Ionis Pharmaceuticals Inc. (ISI) stock suitable for passive index fundsEarnings Growth Summary & Accurate Entry/Exit Alerts - Newser
What Does the Market Think About Ionis Pharmaceuticals Inc? - Benzinga
Is Ionis Pharmaceuticals Inc. (ISI) stock undervalued after correctionJuly 2025 Catalysts & Weekly High Momentum Picks - Newser
Is Ionis Pharmaceuticals Inc. (ISI) stock attractive post correctionFed Meeting & Weekly High Return Stock Forecasts - Newser
How Ionis Pharmaceuticals Inc. (ISI) stock compares with tech leadersMarket Activity Summary & Community Consensus Stock Picks - Newser
Ionis Pharmaceuticals stock hits 52-week high at 82.97 USD By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals stock hits 52-week high at 82.97 USD - Investing.com
Ionis Pharmaceuticals stock maintains Buy rating at TD Cowen on growth outlook - Investing.com Canada
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows - Sahm
FDA grants breakthrough therapy status to Ionis’ Alexander disease drug By Investing.com - Investing.com Canada
Granite Investment Partners LLC Trims Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Why Ionis Pharmaceuticals Inc. (ISI) stock could break out in 2025July 2025 Pullbacks & Daily Volume Surge Trade Alerts - Newser
American Century Companies Inc. Raises Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
How robust is Ionis Pharmaceuticals Inc. (ISI) stock financial position - Newser
What hedge fund activity signals for Ionis Pharmaceuticals Inc. stock2025 Bull vs Bear & Consistent Income Trade Recommendations - Newser
Ionis gets FDA breakthrough therapy status for zilganersen - MSN
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 52-Week HighStill a Buy? - MarketBeat
Ionis Pharmaceuticals (IONS) Gains FDA Breakthrough Therapy Desi - GuruFocus
FDA Grants Breakthrough Therapy Status to Ionis Pharmaceuticals' Zilganersen (IONS) - GuruFocus
Ionis Pharmaceuticals' Investigational Alexander Disease Treatment Granted Breakthrough Therapy Designation - marketscreener.com
FDA grants breakthrough therapy status to Ionis’ Alexander disease drug - Investing.com
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD) - Business Wire
How Ionis Pharmaceuticals Inc. (ISI) stock performs during market turbulenceEntry Point & Low Risk Entry Point Tips - Newser
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):